research Androgenic Effects on Ventricular Repolarization
ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
Search
for
Sort by
Research
30 / 1000+ results 
research P6590Androgenic effects on ventricular repolarization: a translational study from pharmacovigilance databases to iPSC-cardiomyocytes
Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.
research Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study
Low testosterone in men is a risk factor for a specific heart rhythm issue, and testosterone treatment may help prevent it.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
research Development of the AAcQLI : A New Instrument for Assessing Quality of Life in Children With Alopecia Areata
The AAcQLI is a promising tool for assessing quality of life in children with alopecia areata.
research Alfatradiol (0,025 %) - Eine wirksame und sichere Therapieoption zur Behandlung der androgenetischen Alopezie bei Frauen und Männern
Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
research Development and pilot-testing of the Alopecia Areata Assessment Tool (ALTO)
The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.
research Alopecia areata – Quality of Life Questionnaire – formation and validation of the Polish version
The Polish version of the Alopecia Areata Quality of Life Index is a reliable tool for assessing quality of life in Polish-speaking patients with alopecia areata.
research Psychometric validation of the Spanish alopecia areata–life impact questionnaire
The SAALIQ is a reliable tool for measuring the impact of alopecia areata on Spanish-speaking patients' quality of life.
research 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
research The lncRNA HOTAIR/EZH2 interaction inhibitor AC1Q3QWB (AQB) attenuates fibrotic SSc skin tissue re-modelling
AQB reduces harmful skin changes in systemic sclerosis.
research Translation, cultural adaptation and validation of the Brazilian version of the Alopecia Areata Quality of Life Index (AA-QLI-BRA)
The Brazilian version of the Alopecia Areata Quality of Life Index is reliable for assessing patients' quality of life.
research Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes
A SALT score of ≤ 20 indicates meaningful improvement in alopecia areata treatment.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research Assessing Quality of Life in Pediatric Alopecia Areata
The new tool helps measure the impact of alopecia areata on children's quality of life.
research Eclipta alba, An Antioxidant-Rich Memory Enhancer: In-Silicoand In-Vivo Evidence with Specific Insight into Alzheimer’s Disease
Eclipta alba may improve memory and help treat Alzheimer's disease.
research Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C
Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.
research 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
research BH08 Evaluating quality-of-life measures for alopecia: a comparative analysis of Dermatology Life Quality Index and Hospital Anxiety and Depression Scale correlations with disease severity
DLQI is a reasonable quality-of-life measure for alopecia patients, but more research is needed.
research Alefacept for Severe Alopecia Areata
Alefacept does not effectively treat severe alopecia areata.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research Frontal Fibrosing Alopecia Quality of Life Index: A Validated Disease-Specific Questionnaire Involving Women
The FFA-QLI is a reliable tool for assessing quality of life in women with severe Frontal Fibrosing Alopecia.
research 51658 Hair Loss and Quality of Life in Muslim American Women
Hair loss significantly affects the quality of life for Muslim American women, especially those not wearing hijab.
research 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
research Health‐related quality of life and well‐being in pediatric patients with alopecia areata and their caregivers
Children with alopecia areata and their caregivers experience significant emotional and quality of life challenges.
research Baricitinib (Olumiant)
Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
research Quality of life in alopecia areata: A disease specific questionnaire
Alopecia areata greatly affects quality of life, needing psychological support.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss
The updated SALT II tool offers a more precise way to measure scalp hair loss.
research 5PSQ-117 Effectiveness of baricitinib in alopecia areata
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.